China National Medicines Stock Forecast for 2023 - 2025 - 2030
Updated on 04/30/2024
China National Medicines Stock Forecast and Price Target
If the average 2024 price target of ¥44.30 recently set by prominent experts for China National Medicines is met, there would be a potential upside of approximately 27.81% from the last closing price in April, 2024. The high estimate is ¥47.60, and the low is ¥41.00. If you are not interested in 600511 stock, you may be interested in its competitors.
27.81% Upside
China National Medicines Fair Value Forecast for 2023 - 2025 - 2030
China National Medicines's Price has decreased by 100.00% In the last three years, from ¥25.36 to ¥0.00. For next year, the 2 analysts predict Fair Value of ¥47.35, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof ¥51.13, which would mean a seven-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1099 Stock Forecast | Sinopharm Group | Buy |
18
|
HK$20.20 | Buy/Sell | HK$25.81 | 23.66% |
| 601607 Stock Forecast | Shanghai Pharmaceuticals Holdi... | Outperform |
18
|
¥18.06 | Buy/Sell | ¥20.67 | 21.82% |
| 000963 Stock Forecast | Huadong Medicine | Buy |
18
|
¥32.97 | Buy/Sell | ¥52.40 | 34.21% |
| 874 Stock Forecast | Guangzhou Baiyunshan Pharmaceu... | Outperform |
16
|
HK$21.10 | Buy/Sell | HK$24.33 | 8.25% |
| 600998 Stock Forecast | Jointown Pharmaceutical Group | Outperform |
18
|
¥8.08 | Buy/Sell | ¥7.70 | 36.14% |
China National Medicines Revenue Forecast for 2023 - 2025 - 2030
In the last three years, China National Medicines's Revenue has grown, increasing from ¥40.38B to ¥49.70B – an increase of 23.08%. In the following year, the 0 analysts surveyed believe that China National Medicines's Revenue will decrease by 6.48%, reaching ¥46.48B. According to professionals, by 2030, China National Medicines's Revenue will have decreased by 5.97%, falling down to ¥46.73B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600056 Stock Forecast | China Meheco Group | - |
18
|
¥10.38 | Buy/Sell | ¥17.87 | 22.93% |
| 301015 Stock Forecast | Qingdao Baheal Medical INC. | Buy |
14
|
¥31.57 | Buy/Sell | ¥39.98 | 61.55% |
| 000078 Stock Forecast | Shenzhen Neptunus Bioengineeri... | - |
13
|
¥2.32 | Buy/Sell | ¥9.24 | -100.00% |
.jpg)
China National Medicines Dividend per Share Forecast for 2023 - 2025 - 2030
China National Medicines's Dividend per Share has increased by 54.55% In the last three years, going from ¥0.55 to ¥0.85. In the next year, analysts expect Dividend per Share to reach ¥0.90 – an increase of 5.88%. For the next seven years, the forecast is for Dividend per Share to grow by 20.78%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 603368 Stock Forecast | Guangxi LiuYao Group | Buy |
18
|
¥17.95 | Buy/Sell | ¥0.00 | 41.06% |
| 002589 Stock Forecast | Realcan Pharmaceutical Group | - |
11
|
¥2.68 | Buy/Sell | ¥11.80 | -100.00% |
| 000705 Stock Forecast | Zhejiang Zhenyuan Share | - |
18
|
¥8.27 | Buy/Sell | ¥0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1345 Stock Forecast | Shanghai Pioneer Holding Ltd | - |
18
|
HK$1.90 | Buy/Sell | HK$2.93 | -100.00% |
| 2289 Stock Forecast | Charmacy Pharmaceutical | - |
14
|
HK$13.80 | Buy/Sell | HK$8.72 | -100.00% |
| 6833 Stock Forecast | Sinco Pharmaceuticals Holdings | - |
12
|
HK$0.25 | Buy/Sell | HK$0.46 | -100.00% |
China National Medicines EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, China National Medicines's EBITDA has grown by 48.77%, from ¥1.67B to ¥2.48B. For the next year, analysts are expecting EBITDA to reach ¥2.99B – an increase of 20.40%. Over the next seven years, experts predict that EBITDA will grow by 38.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1110 Stock Forecast | Kingworld Medicines Group | - |
0
|
HK$0.54 | Buy/Sell | HK$0.00 | -100.00% |
| BIMI Stock Forecast | BIMI International Medical | - |
4
|
$2.91 | Buy/Sell | $0.00 | -100.00% |
| 1011 Stock Forecast | China NT Pharma Group Company | - |
0
|
HK$0.03 | Buy/Sell | HK$1.95 | -100.00% |
China National Medicines EBIT Forecast for 2023 - 2025 - 2030
In the last three years, China National Medicines's EBIT has grown from ¥1.57B to ¥2.37B – a 51.61% increase. Next year, analysts are expecting EBIT to reach ¥3.35B – an increase of 41.21%. Over the next seven years, the forecast is for EBIT to grow by 54.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 2211 Stock Forecast | Universal Health International... | - |
-7
|
HK$0.04 | Buy/Sell | HK$29.30 | -100.00% |
| CNBI Stock Forecast | China BCT Pharmacy Group | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| A2H Stock Forecast | Anti-Aging House Holding | - |
0
|
0.00 | Buy/Sell | 0.00 | 0.00% |
China National Medicines EPS Price Prediction Forecast for 2023 - 2025 - 2030
China National Medicines's EPS has decreased by 100.00% In the last three years, from ¥1.73 to ¥0.00. For next year, the 2 analysts predict EPS of ¥3.23, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof ¥3.49, which would mean a seven-year growth forecast of 100.00%.
Site Navigation
.jpg)